On Thursday, the FDA granted full approval to Humacyte, Inc.'s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Patent provides coverage into 2043 for key aspects of how Symvess is manufactured, sterilized, stored and shipped.DURHAM, N.C., ...
Humacyte, a bioengineering company, went public through a SPAC merger in 2015, with a market value of $1.1 billion. The company has received FDA's RMAT designation for three indications, including ...
The FDA granted a Priority Review in February 2024 and was assigned a PDUFA date of August 10, 2024. ATEV is a bioengineered human tissue designed to be a universally implantable vascular conduit for ...
Bioengineered organs are no longer just structural substitutes. A review published in Trends in Biotechnology introduces a groundbreaking concept: biohybrid-engineered tissue (BHET) platforms—living ...
A new bioengineered neuronal circuit board "BioConNet" allows scientists to artificially engineer human brain-like wiring at scale and can be used to engineer any possible circuit. The fully ...
A new type of bioengineered blood vessel has shown strong results in treating severe vascular injuries, potentially offering vascular surgeons a better alternative to synthetic grafts when patients' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results